Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2323 - Risk of cardiovascular late effects in breast cancer survivors: a population-based study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Jihyoun Lee

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

J. Lee1, I.Y. Chung2, Z. Kim3, H. Hur4, J.W. Lee2, H.J. Youn5

Author affiliations

  • 1 Surgery, Soonchunhyang University Hospital Seoul, 140-743 - Seoul/KR
  • 2 Surgery, Asan Medical Center, Seoul/KR
  • 3 Surgery, Soonchunhyang University Hospital, -743 - Bucheon/KR
  • 4 Surgery, National Health Insurance Service Ilsan Hospital, Goyang/KR
  • 5 Surgery, Chonbuk National University Medical School, Jeonju/KR
More

Resources

Abstract 2323

Background

Cardiovascular diseases are one of the late effects of breast cancer treatment that can impair survival. We reviewed the development of cardiac disease in breast cancer survivor using nationwide database.

Methods

A nation-wide retrospective cohort study was conducted using National Health Information Database which provides a whole set of claimed medical information, such as ICD-10 diagnosis and prescription data. We performed 1:5 age-sex matching with the non-cancer controls. Incidence of MI and CHF was evaluated for adjuvant treatment modalities, with adjustment of age and previous comorbidities (diabetes, hypertension, and hyperlipidemia).

Results

A total of 112,058 cases (554,801 person-years) and 560,290 controls (2,916,459 person-years) were evaluated. Risk of MI (hazard ratio (HR) 1.258, 95% confidence interval (CI) 1.168 - 1.355) and CHF (HR 1.86, 95% CI 1.753 – 1.973) was higher in breast cancer survivors than in non-cancer controls. Younger survivors (age 50 or less) showed the highest risk of MI (HR 1.73, 95% CI 1.512 – 1.979) and CHF (HR 3.557, 95% CI 3.174 – 3.986). Within one year of breast cancer diagnosis, the cumulative incidences of MI and CHF were significantly high in survivors. The cumulative incidence of CHF in breast cancer survivors was continuously higher than the control group, in contrast to that of MI showed similar pattern to controls. Taxane use was associated with development of MI (HR 1.284, 95% CI 1.074 – 1.534) and CHF (HR 1.65, 95% CI 1.444 – 1.887).

Conclusions

Incidence of MI and CHF were higher in breast cancer survivor than the non-cancer controls. The elevated risk of MI and CHF in early phase of survivorship should be noted, especially in young age group.

Clinical trial identification

Legal entity responsible for the study

The Study of Multi-disciplinary Teamwork for breast cancer survivorship (SMARTSHIP).

Funding

Korean Breast Cancer Society.

Editorial Acknowledgement

The authors appreciate to the Korean Breast Cancer Society and the Study of Multi-dicsiplinary Teamwork for breast cancer survivorship (SMARTSHIP)

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.